Sep 2, 2022 - Economy

FTC loses bid to block Illumina's $7 billion buyout of Grail

Dan Primack

Illustration of a caduceus with a gavel in the center. — Illustration: Aïda Amer/Axios

Genetic testing company Illumina on Thursday prevailed over the Federal Trade Commission in an administrative court trial over its $7.1 billion acquisition of Grail, a Menlo Park, Calif.-based developer of liquid biopsies for early cancer detection. Illumina had founded Grail, but spun it off in 2017.

Why it matters: This is a stinging loss for the FTC, particularly given that the case was heard by its in-house court, and a huge win for Illumina's decision to complete the merger in spite of ongoing litigation.

Look ahead: An European Commission decision on the merger is expected next week, with Illumina disclosing last week that it's reserved $453 million in "legal contingencies" for a negative ruling.

Moreover, Brussels could force Illumina to forfeit up to 10% of revenue (including Grail revenue) if found to have violated rules against completing mergers prior to final EC approval.
Also, expect the FTC to appeal.

Add Axios on Google

FTC loses bid to block Illumina's $7 billion buyout of Grail

What to read next